Phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with the progressive autoimmune kidney ...

A total of 340 biopsy-confirmed IgAN patients were randomised to daily oral Vanrafia or a placebo for approximately 132 weeks.

It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...

Long-term data from the phase 3 ALIGN trial reinforce the safety and efficacy of atrasentan for patients with immunoglobulin A nephropathy.

Kidney disease often creeps in silently, and many patients aren’t diagnosed until major damage is already done. New research ...

Older adults living with heart failure with preserved ejection fraction (HFpEF) are frequently labeled as having chronic ...

Kidney aging rarely draws attention until something goes wrong. Over time, these organs quietly lose strength, filter less efficiently, and struggle to keep the body balanced. A new study now brings ...

Aims Heart failure (HF) often coexists with chronic kidney disease (CKD), impacting prognosis. This study aims to evaluate ...

Originally developed as a more-potent follow-up to Roche's long-established CD20-directed antibody Rituxan (rituximab) for ...

Comprehensive phosphorus management preserves residual renal function, considers dialysis modality, and minimizes intervention burden.

What if a simple urine test could warn you about hidden kidney damage before symptoms even appear? It can-and that's exactly ...